- Home
- TII vs BDTX Comparison
TII vs BDTX Comparison
Compare TII & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | BDTX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.5M | 171.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TII | BDTX |
|---|---|---|
| Price | $2.86 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.38 | ★ $9.67 |
| AVG Volume (30 Days) | 272.3K | ★ 510.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.60 |
| 52 Week High | $5.65 | $4.94 |
Technical Indicators
Market Signals| Indicator | TII | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 39.67 |
| Support Level | $2.75 | $1.76 |
| Resistance Level | $3.14 | $1.90 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 19.85 | 17.23 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.